Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer

Department of Pharmacy, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Kumamoto, Kumamoto, 860-0008, Japan.
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.77). 12/2011; 69(3):845-8. DOI: 10.1007/s00280-011-1802-x
Source: PubMed


We examined a method to determine the dose of carboplatin and the timing of hemodialysis in carboplatin-based chemotherapy for a hemodialysis patient with cancer.
Carboplatin-based chemotherapy was performed for a patient with small-cell lung cancer who was receiving hemodialysis. The dose of carboplatin was calculated based on body surface area in the first cycle (480 mg/body, Day 1) and based on the Calvert formula with the aim of achieving AUC of 5 mg/ml min in the second cycle (170 mg/body, Day 1). Carboplatin was continuously infused for 1 h on Day 1 of each cycle. Hemodialysis was performed for 4 h beginning 1 h after administration of carboplatin.
The AUC of free carboplatin administered in the first and second cycles was 13.45 and 5.74 mg/ml min, respectively, and t (1/2) was 24.66 and 21.84 h, respectively. Protein binding ratio depended on the time after administration and reached a value ≥50% only at ≥24 h administration.
Based on the results of this study, a value close to the targeted AUC can be obtained in a hemodialysis patient with cancer when carboplatin is administered at a dose determined based on the Calvert formula. These results may be useful to achieve a targeted AUC in hemodialysis patients. A certain amount of carboplatin can be eliminated by performing hemodialysis in an early phase when protein binding ratio is low after transition to the elimination phase to enable stable the concentration.

12 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: We retrospectively investigated the efficacy and safety of temsirolimus, an inhibitor of the mammalian target of rapamycin, in patients with metastatic renal cell carcinoma (mRCC) on hemodialysis (HD). Methods: This study included ten HD patients who were diagnosed with mRCC following radical nephrectomy and subsequently treated with temsirolimus between December 2010 and June 2012. Medical records of these patients were reviewed to evaluate the response to temsirolimus and treatment-related toxicities. Results: Baseline characteristics of the patients are as follows: median age was 61 years, five patients had a Karnofsky performance status of ≤80, and two, six, and two patients were classified into favorable, intermediate, and poor risk group, respectively, according to the Memorial Sloan-Kettering Cancer Center risk model. Initially, all patients received 25 mg intravenous temsirolimus weekly; however, dose modification was necessary in four patients, resulting in a relative dose intensity of 89.5 % throughout this study. All patients, except for one with progressive disease, were judged to have stable disease following treatment with temsirolimus. Six patients are still under treatment with temsirolimus, whereas four have stopped receiving temsirolimus because of the occurrence of progressive disease in three and that of adverse events (AEs) in one. Although all patients experienced AEs related to temsirolimus, severe AEs corresponding to ≥ grade 3 occurred in only four, including thrombocytopenia in two, anemia in one, and asthenia in one. Conclusions: Treatment with temsirolimus is well tolerated and could provide comparatively favorable cancer control in Japanese mRCC patients undergoing HD.
    No preview · Article · Nov 2012 · International Journal of Clinical Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Treatment of malignancy in patients with chronic renal failure has been an issue of debate since mid 1970’s. Any stage of chronic renal disease is seen in patients with malignancy with a high frequency such as 50-60%. Nowadays, incidence of end-stage renal failure is increasing worldwide and the majority of these patients undergo hemodialysis. Doses of the cytotoxic treatment and application of the drugs with appropriate timing according to the hemodialy- sis periods is important in these patients because of the side effects and ef- ficacy of the treatment; when there is a coexisting malignancy. In this paper, tolerance and dose arrangement of the chemotheraupetics used in treat- ment of solid tumors in patient with end stage renal failure who undergo hemodialysis have been reviewed with current litearure. Keywords: hemodialysis, cancer, chemotherapy
    Full-text · Article · Jan 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Small cell lung cancer is primarily treated with chemotherapy. For patients with end-stage renal disease (ESRD), systemic chemotherapy is often challenging since renal excretion of chemotherapeutic agents might be decreased due to impaired renal function, leading to increased toxicity. No consensus is made so far regarding appropriate dosage and combination of chemotherapeutic agents for patients on hemodialysis. We report two cases of chemotherapy without significant toxicity in small cell lung cancer patients who were on hemodialysis for ESRD.
    Preview · Article · Jan 2014
Show more